EGFR and lung carcinoma: In patients with lung adenocarcinoma, PDZK1IP1 expression may be used to predict a patient’s response to cisplatin, carboplatin, EGFR inhibitors, or bortezomib, which is clinically beneficial for patients with lung cancer [45].